...
BCRXSMALL

BioCryst Pharmaceuticals, Inc.

HealthcareBiotechnology
$8.75
$0.01(+10.76%)
52W$6.00
$11.31
FinancialsValuationvs AGIO
Updated Mar 2, 12:00 AM
RSI71
RS Rating60/99
Beta0.74
Volatility49%
F-Score7/9
Mkt Cap$1.9B
WEAKENING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

WEAKENING

BioCryst Pharmaceuticals, Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is moderate (RS Rating: 60), indicating performance broadly in line with the market. Earnings growth of 10% provides fundamental context to the price action. However, price is extended 23% above the 50-day line, increasing the risk of a mean reversion.

Relative Strength
60
out of 99
Average
Trend Score
1/4
Minervini Criteria
WEAKENING
Risk (Beta)
0.74
vs S&P 500
DEFENSIVE
52W Position
52%
from 52W low
Mid Range
Trend & Momentum Analysis

Trend Template (Minervini)

WEAKENING1/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$7.13
50 SMA > 100 SMA$7.15
100 SMA > 150 SMA$7.46
150 SMA > 200 SMA$8.04

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$7.03+24.51%ABOVE
50 SMA$7.13+22.70%ABOVE
100 SMA$7.15+22.41%ABOVE
150 SMA$7.46+17.30%ABOVE
200 SMA$8.04+8.83%ABOVE

Price Performance

1D+10.8%
1W+15.4%
1M+31.4%
3M+21.9%
6M+3.3%
YTD+16.7%
1Y+1.6%
3Y-0.4%
52-Week Trading Range52% from low
$8.75
52W Low$6.00
52W High$11.31

Technical Indicators

RSI (14)OVERBOUGHT
70.7
305070
VCP ScoreHOT
7/10
Base depth: 29.7%

Risk Profile

Beta
0.74
52W Vol
49%
ATR
$0.33
Max DD (1Y)
-44%

Volume Analysis

Today
8
50D Avg
3.55M
Vol Ratio
0.00x
Liquidity
MODERATE

Earnings Momentum

Q1'25+100%
$0.00
Q2'25+133%
$0.02
Q3'25+184%
$0.06
Q4'25+962%
$1.12
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+33.61%
5 Years:+117.89%
3 Years:+47.82%
TTM:+94.10%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+378.77%

Stock Price CAGR

10 Years:+15.96%
5 Years:-6.09%
3 Years:-0.38%
1 Year:+1.63%

Return on Equity

10Y Avg:-1105.0%
5Y Avg:—
3Y Avg:—
Last Year:—

Key Metrics

Market Cap$1.9B
Gross Margin97.8%
Net Margin30.2%
Piotroski F-Score7/9

More BCRX Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

BCRX vs AGIOAGIOVRTXASNDBBIO

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 60 meansBCRX outperformed 60% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.74 means 26% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 7/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 7/10 with HOT status.

Frequently Asked Questions

Is BCRX in an uptrend right now?

BCRX has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.

Is BCRX overbought or oversold?

BCRX's RSI (14) is 71. The stock is in overbought territory (RSI > 70), which may signal a pullback.

Is BCRX outperforming the market?

BCRX has a Relative Strength (RS) Rating of 60 out of 99. BCRX is performing about average compared to the market.

Where is BCRX in its 52-week range?

BCRX is trading at $8.75, which is 77% of its 52-week high ($11.31) and 52% above its 52-week low ($6.00).

How volatile is BCRX?

BCRX has a Beta of 0.74 and 52-week volatility of 49%. It's less volatile than the S&P 500 - generally more stable.